Metagenomi, Inc. Common Stock - Asset Resilience Ratio
Metagenomi, Inc. Common Stock (MGX) has an Asset Resilience Ratio of 58.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Metagenomi, Inc. Common Stock's Asset Resilience Ratio has changed over time. Check Metagenomi, Inc. Common Stock PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Metagenomi, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Metagenomi, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $114.86 Million | 58.32% |
| Total Liquid Assets | $114.86 Million | 58.32% |
Asset Resilience Insights
- Very High Liquidity: Metagenomi, Inc. Common Stock maintains exceptional liquid asset reserves at 58.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Metagenomi, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Metagenomi, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Metagenomi, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 53.86% | $119.08 Million | $221.10 Million | -14.20pp |
| 2024-09-30 | 68.06% | $220.92 Million | $324.60 Million | +32.27pp |
| 2023-09-30 | 35.79% | $130.58 Million | $364.84 Million | -7.08pp |
| 2022-09-30 | 42.87% | $177.69 Million | $414.49 Million | -5.62pp |
| 2021-09-30 | 48.49% | $68.86 Million | $141.99 Million | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more